ARK Investment Management LLC Has $579.16 Million Stake in Tempus AI, Inc. $TEM

ARK Investment Management LLC lessened its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 3.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,175,767 shares of the company’s stock after selling 246,003 shares during the period. Tempus AI comprises 3.4% of ARK Investment Management LLC’s investment portfolio, making the stock its 9th biggest holding. ARK Investment Management LLC’s holdings in Tempus AI were worth $579,156,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Tempus AI by 22.1% during the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after buying an additional 1,706,837 shares during the last quarter. AQR Capital Management LLC purchased a new stake in Tempus AI in the 2nd quarter valued at $54,020,000. Geode Capital Management LLC lifted its stake in Tempus AI by 411.4% during the 2nd quarter. Geode Capital Management LLC now owns 649,420 shares of the company’s stock valued at $41,264,000 after acquiring an additional 522,443 shares in the last quarter. Marex Group plc bought a new position in Tempus AI during the 2nd quarter valued at $26,620,000. Finally, Gilder Gagnon Howe & Co. LLC boosted its holdings in Tempus AI by 1,747.6% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 413,081 shares of the company’s stock worth $26,247,000 after acquiring an additional 390,723 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Insider Buying and Selling

In related news, CAO Ryan M. Bartolucci sold 2,902 shares of Tempus AI stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $171,363.10. Following the transaction, the chief accounting officer directly owned 41,159 shares of the company’s stock, valued at $2,430,438.95. The trade was a 6.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO James William Rogers sold 10,084 shares of Tempus AI stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $595,460.20. Following the completion of the sale, the chief financial officer owned 101,166 shares in the company, valued at approximately $5,973,852.30. This represents a 9.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 590,109 shares of company stock worth $37,056,566 over the last ninety days. Corporate insiders own 26.27% of the company’s stock.

Tempus AI Stock Performance

Shares of TEM opened at $51.29 on Thursday. Tempus AI, Inc. has a 12-month low of $36.22 and a 12-month high of $104.32. The company has a current ratio of 3.13, a quick ratio of 3.00 and a debt-to-equity ratio of 2.52. The company has a market cap of $9.13 billion, a PE ratio of -36.38 and a beta of 5.29. The stock has a 50-day moving average price of $60.57 and a 200-day moving average price of $72.91.

Analyst Ratings Changes

A number of brokerages have issued reports on TEM. Morgan Stanley reduced their price objective on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a research report on Tuesday. JPMorgan Chase & Co. reduced their target price on Tempus AI from $80.00 to $60.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Canaccord Genuity Group dropped their price target on Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, December 22nd. Wall Street Zen cut Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, HC Wainwright reduced their price objective on Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $78.15.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.